CytomX Therapeutics, Inc. (“CytomX”) has retained Major, Lindsey & Africa (“MLA”) on an exclusive basis to conduct a search for their Senior Vice President, Intellectual Property (SVP of IP or Counsel), to be located in South San Francisco, California. Interested candidates, please respond to the MLA recruiter who contacted you about this search or directly to CytomXSVPIP@mlaglobal.com. Please do not contact CytomX directly; all resumes sent to CytomX will be routed to MLA for handling and may cause delays.
Senior Vice President, Intellectual Property
CytomX Therapeutics, Inc. seeks an accomplished patent attorney to lead and grow its Intellectual Property function. The SVP of IP will develop, oversee and champion CytomX’s comprehensive IP strategy, processes and portfolio as we move toward commercialization. In particular, he or she will manage CytomX’s growing IP team; develop and maintain its international patent portfolio; monitor and respond to competitor activity; manage potential adversarial actions; and oversee the IP strategy for product life cycles. Reporting to CytomX’s General Counsel, the successful candidate will have a background in life science, including antibody technology experience, and will have managed portfolio strategy for a commercial life science company. This position will be an integral part of CytomX’s management team.
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072), a PD-1-targeting Probody therapeutic wholly owned by CytomX (CX-188) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The pipeline also includes first-in-class Probody drug conjugates against highly attractive targets including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029) are among cancer targets that have been considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. CytomX and its partners have four programs in the clinic. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc.
South San Francisco, CA.
Yes, this is a national search.
Compensation & Leveling:
Competitive and commensurate with the candidate’s level of experience.
20 years of experience in IP law in the life sciences sector and in-house experience (5-10 years) at a commercial pharmaceutical/biotech company desired.
Employer will assist with relocation costs.
Internal Number: O-2318170
About Major, Lindsey & Africa
Founded in 1982, Major, Lindsey & Africa is the world’s largest and most experienced legal search firm. Combining local market knowledge and a global recruiting network, MLA has earned recognition for its track record of successful General Counsel, Corporate Counsel, Partner, Associate and Law Firm Management placements. With offices throughout the U.S., Hong Kong, London, and Tokyo, MLA recruiters are dedicated to understanding and meeting clients’ and candidates’ needs while maintaining the highest degree of professionalism and confidentiality. MLA considers every search a diversity search, and has been committed to diversity in the law since its inception. For these reasons, MLA was voted “Best Legal Search Firm in the U.S.” in the most recent national survey of America’s top law firms. To learn more about MLA, please visit our website at www.mlaglobal.com.